ST Drugs that Treat Glioblastoma Multiforme through a Novel Mechanism


To conduct preclinical testing of a novel small-molecule treatment for glioblastoma multiforme, a typically fatal brain cancer, and for colorectal cancer

Anticipated Impact: 

An inexpensive, effective treatment for brain, colorectal, and other cancers


Glioblastoma multiforme (GBM) is a rare but inevitably fatal brain tumor that has two relatively ineffective therapies at present. Proposed is an in vivo study, using a state-of-the-art mouse model, of “ST drugs," which target a class of cell-surface receptors. That class of receptors is the target of approximately 40% of the drugs on the market. ST drugs may be a platform, i.e., a group of drugs that may work against other cancers and diseases. Efficacy against the four known subtypes of GBM, as well as safety and toxicity of the ST drugs, will be evaluated. To increase the likelihood of commercialization and to test ST drugs against an additional cancer, a supplement of $73,000 was made in 2015 for a preclinical testing of efficacy in a colorectal cancer model.

Collaborating organizations: University of Washington; Agile DiscoveryPartners, LLC; The Jackson Laboratory; Histology Consultation Services, Inc.

Stella Therapeutics named Jeremy Blum as principal investigator, replacing Eric Horne, in July 2015.

Brain Cancer Treatment
Colorectal Cancer Treatment

Grant Update

Principal Investigator:
Jeremy Blum
Grantee Organization:
Stella Therapeutics
Grant Title:
ST Drugs that Treat Glioblastoma Multiforme through a Novel Mechanism
Grant Cohort and Year:
2013 Proof of Concept (03)
Grant Period:
12/01/2013 - 11/30/2016 (Completed)
Grant Amount:
Stella Therapeutics’ LSDF funded program, the Company has successfully completed multiple milestones towards evaluating the in vivo efficacy and safety of its novel therapy to treat the brain cancer (glioblastoma multiforme) and colon cancer. Specifically, Stella Therapeutics successfully demonstrated the scalability and stability of its most promising reagents. Exploratory toxicity confirmed these compounds are well tolerated and pharmacokinetic analysis confirms the ability of these compounds to cross the blood brain barrier at therapeutically relevant concentrations. Most recent studies show highly significantly in vivo efficacy of these reagents to increase mean survival in multiple mouse tumor models. The Company has also successfully secured the necessary resources and collaborations with key opinion leaders needed as the company advances its lead candidate.

Impact in Washington

Location of LSDF Grantee
Locations of Collaborations/Areas of Impact

Legislative Districts:
11, 34, 36, 37, 42, 43, 46

Health Impacts

Brain Cancer Treatment
Colorectal Cancer Treatment